ArticleFrontiers in public health2025
Global, regional, and national disease burden of tobacco-related Alzheimer's disease among individuals over the age of 55: a global burden of disease study.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease is a progressive neurodegenerative disorder characterized by an insidious onset. Numerous studies have identified a significant association between tobacco use and Alzheimer's disease. This study aims to explore the epidemiological patterns and trends concerning tobacco-related Alzheimer's disease at global, national and regional levels. Methods: We analyzed data on mortality, age-standardized DALY rate (ASDR), and estimated annual percentage changes (EAPCs) sourced from the Global Burden of Disease data for 2021. The analysis was further stratified by country and region, socio-demographic index (SDI), gender, and age. A Bayesian Age-Period-Cohort (BAPC) model was employed to project the global burden in the future. Results: In 2021, the total burden revealed a decline in the number of deaths and ASDR compared to 1990. The highest proportions of mortality and ASDR were observed in the age group over 95 years. The disease burden among men was significantly higher than of among women, approximately three times greater. Conversely, in Australia and North America, the burden of disease among women surpassed that of men. In most of the 21 regions worldwide, both mortality and ASDRs have decreased since 1990, and intra-regional mortality rates have declined as SDI has increased. It is anticipated that the burden will continue to gradually decrease from 2021 to 2040. Conclusion: Although the global burden of tobacco-related Alzheimer's disease among the older adults declined from 1990 to 2021, significant disparities existed across regions, age groups, sex, and SDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.